Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis Maria C. Cid – Hospital Clinic Barcelona
11:45 AM – 12:00 PM ET
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial John H. Stone, MD, MPH – Massachusetts General Hospital Rheumatology Unit, Harvard Medical School
12:00 PM – 12:15 PM ET
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) Thomas M. MacDonald, MD, FRCP – University of Dundee
12:15 PM – 12:30 PM ET
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA) Dinesh Khanna, MD, MSc – University of Michigan
12:30 PM – 12:45 PM ET
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734 Victoria P. Werth, MD – University of Pennsylvania
12:45 PM – 1:00 PM ET
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Atul Deodhar, MD – Oregon Health & Science University
.png "Jennifer Anolik, MD, PhD photo")
